Products that ASSESS, TRAIN and MONITOR the Brain

Brain Resource Limited (ASX: BRC, OTC: BRRZY)Investor Presentation

November 2015

For

per

sona

l use

onl

y

About Brain Resource

1

• Brain Resource Limited was founded in 2000 based on decades of research by a global multidisciplinary team including many Key Opinion Leaders.

• Offices in San Francisco and Sydney, with majority of business and clients in the US.

• Leading provider of online scientifically validated scalable products that Assess, Train and Monitor the brain to increase brain health.

• The MyBrainSolutions® products targets a large unmet need and current clients include more than 40 brand name corporations and 92 addiction clinics.

• Developing Depression and ADHD treatment prediction tests and has the world’s largest standardised brain database that underpins all development and products.

• 600,000 have used a Brain Resource product to date and $50m has been spent on development.

• Plans are progressing to list on NASDAQ to better align with business, currently listed on the ASX.

For

per

sona

l use

onl

y

Large untapped sector seeking solutions

• Brain Health is a large untapped sector with strong new macro drivers:• the market is now brain aware and seeking solutions.• significant new healthcare reforms (Obamacare, Mental Health Parity).

• MyBrainSolutions current client revenue model: • Employers charged Per Employee Per month (av employer $40,000 pa multi year contracts).• Addiction Clinics charged $70 per user (av clinic $15,000 pa).

• MyBrainSolutions is currently used in 4 large US markets, a $300million+ opportunity:

1) Employer: 18,000 US employers employ 61 million.2) Addiction: 2.5 million patients treated in 14,000 clinics.3) Depression: 85 million clinical visits pa.4) Consumer: 20 million untreated addicts and general

consumer wellness.

2

For

per

sona

l use

onl

y

Wide applicability of MyBrainSolutions.com

Benefits of using MyBrainSolutions, a highly versatile platform that applies to many user groups:

• Employees / consumers: build employee resilience (stress management, ‘bouncebackability’) and improved performance and drive productivity gains and health care cost savings for employer.

• Addiction: improved patient care by clinicians informed by objective patient Assessment, Training to aid patients create new brain habit of self control and circuit break cravings, and consilidate gains through Monitoring outcomes.

3

For

per

sona

l use

onl

y

1. Employer: Recurring per employee revenues Escalating growth via distributor partnerships

9

16

27

35

40

JUN 12 JUNE 13 JUN 14 JUN 15 YTD 16

Employer / Distributor Contracts

4

For

per

sona

l use

onl

y

• $100 million market opportunity.

• Revenues based on a Per Employee Per Month basis – FY15 largest client billed $135,000 with $26,000 av revenue for contributing clients. Uplift potential from third party verified ROI numbers.

• Strong distribution now in place (Aetna, Mercer, Kaiser, Humana etc) to escalate penetration of the 18,000 employers and 61 million employees beyond our current $1 million in contracts and 500,000 employees covered.

• $10 million initial target based on winning 300 av size clients worth $40,000 pa – big potential impact from winning the 1,000 employ more than 10,000 eg our Boeing win worth > $500,000 pa.

• Annuity revenue but a longer sales cycle.

• Not lost one client to date and our strong differentiators in the market have allowed us to be the only one to penetrate (key has been strong science underpinnings that have withstood multiple due diligence).

Employer revenues and prospects

5

For

per

sona

l use

onl

y

2. Addiction: Per user revenuesNew intiative with rapid uptake, Adding clinics at the rate of ~2 per week

6

4

12

41

72

100

JUN13 JUN 14 DEC 14 JUN 15 YTD 16

Addiction contracted clinics

For

per

sona

l use

onl

y

• $200 million market opportunity for addicts treated in specialist care.

• Revenues based on $70 per user (with reimbursable CPT codes) - FY15 largest clinic billed $70,000 and $5,000 av revenue for contributing clients.

• Rapid growth in contracted clinics now allowing us to target large providers eg Acadia Healthcare potentially worth our $10 million target alone ($7 million from its 9,000 beds and $3 million from its 40,000 daily medication patients). Currently have 8 Acadia Healthcare clinics signed.

• $10 million initial target based on winning 500 centers/150,000 patients out of total market of 14,000 clinics ($15,000-$20,000 average).

• Annuity revenue from contracted clinics.

• Meeting large unmet need for objective assessment and evidence based tools to help recovery.

Context is that FY15 loss of $2.5 million could be transformed by one large deal.

Addiction revenues and prospects

7

For

per

sona

l use

onl

y

8

• All content is underpinned by the standardized Brain Resource International Database, the largest of its kind in the world and developed with input from many Key Opinion Leaders.

• 300,000 datasets, 400 users accessing data (through Brainnet.net) and hundreds of publications – also currently running iSPOT study, the largest of its kind in the world in treatment prediction in depression and ADHD.

• The Database informs about the underlying mechanisms which allows us to drive new report and training content based on these insights. The standardisation of the database means we can instantly compare new data to the relevant peer groups.

• FDA 510k approval granted in 2005 for platform (K050192), patented components and Information Security Management System ISO /IEC 27001:2005 certified.

• Standardization, integration and scale are hard to implement and replicate, with the Data analysis tools and the Data collection taking decades to get to this point.

Strong science underpinnings and platform for growth

For

per

sona

l use

onl

y

3. Consumer: Brain Health Brain TrainingWhat sets MyBrainSolutions apart from competition.

Lumosity has softened the ground for competition in the Consumer market

Coupling of emotional with cognitive training

Use of a validated assessment

A strong foundation built and used by researchers, clinicians and employers

Underpinned by Brain Resource International Database

Specific target market focus

9

The key distinctions of MyBrainSolutions are:

1. The scientific validation of the ASESSMENT (of key brain capacities that direct Training new habits)

2. The focus of engaging tools for STRESS REDUCTION (Relaxation Room), SHIFTING NEGATIVE to POSITIVE THINKING (Thought Tamer) and POSITIVITY TRAINING (Happy Seeker) – in addition to games that boost memory and focusF

or p

erso

nal u

se o

nly

3. Consumer: Brain Health Focus on partnering with established companies in the consumer sector.

• Sharecare strategic alliance:

• First consumer partnering deal with Sharecare.

• Sharecare, a health and wellness engagement platform that has 87 million registered users, was founded by Jeff Arnold (WebMD) and Dr Oz in partnership with Harpo Productions (Oprah Winfrey), Sony, Discovery Communications. It is partnered with AARP, American Diabetes Association, American Heart Association.

• Sharecare offering that includes MyBrainSolutions content expected to launch early 2016.

• Untreated addicts:

• Next consumer offering will be to offer MyBrainSolutions to an addressable segment of the 20 million untreated addicts, to provide them with an online recovery aid.

• 1m untreated perceived a need for treatment

10

For

per

sona

l use

onl

y

4. iSPOT study - Impacting psychiatry

• “iSPOT-D is currently the largest personalized medicine research study in mental health” Psychiatric News (American Psychiatric Association)

• Addressing the need for objectivity in treatment decision, as opposed to current trial and error.

• iSPOT is a $18m practical trial mirroring routine clinical practice, commenced 2007 – data acquired from 1,800 depressed patients (plus 400 healthy controls) and 500 ADHD . Drugs tested were Sertraline (Zoloft 40m prescriptions / 280m total market), Escitalopram (Lexapro 23m prescriptions), Venlafaxine (Effexor 18m prescriptions).

• 20 global acquisition sites including Stanford, Cornell, Miami, Sydney and KOL’s include Prof J Rush from Duke the principal investigator on the NIMH STAR*D study, Prof A Schatzberg former head of the APA and Dean of Psychiatry at Stanford, Dr Steve Koslow, former NIMH director and head of the Human Brain Project.

• 20+ publications to date (including trial protocol) – iSPOT is the first study to publish outcomes in each of the five key Depression study measures (Genetics, MRI, EEG, Cognition, Clinical -full publication list www.brainrsource.com/research/ispot/ispotd.

• Major expediture on data acquisition phase complete, numerous analyses underway to identify new tests for Depression and ADHD.

11

For

per

sona

l use

onl

y

Sertraline the first test to replicate and others in development

• The first test that has replicated is to predict who will not respond to Sertraline based on cognition measures and will be submitted to FDA under ‘De Novo’ pathway. We will also be reporting our other two drug results flagging further analysis that we intend to undertake.

• We will be further develop and expand the cognitive tests by adding brain function and genomics measures (either alone or in combination with cognition) using the data that has already been collected as part of the iSPOT-D study.

• Tests to be add ons to MyBrainSolutions platform (85 million Primary Care Physician visits pa with existing reimbursement codes (eg: CPT 96120 pays $90 average).

12

For

per

sona

l use

onl

y

Key calendar year 2016 milestones

• New clinical portal to help drive Addiction revenues

• Expansion of Sharecare strategic alliance.

• On-going growth in Employer and Addiction clinic contracts

• Progress with Brain Tests and regulatory approvals

• Build relationships with major players in the Addiction market

• Increase traction with Employer distributor work forces

• Launch of MyBrainSolutions to consumers starting with Untreated addicts

• NASDAQ listing

13

For

per

sona

l use

onl

y

MyBrainSolutions Personnel (Total = 25 FTE)

Evian Gordon, MD PhD is CEO, Chairman of the Board and founder of Brain Resource. He has more than 30 years experience in human brain research and is considered as one of the originators of the field of integrative neuroscience. He has authored more than 300 peer reviewed publications.

Dan Segal BCom, MSc is COO/CFO, Executive Director and founder of Brain Resource. He was previously a Director in the Equities Research Department at Citigroup. His science studies were in Physics and he has been a member of the Institute of Chartered Accountants for close to 30 years.

Tom Clements, MBA is VP of Sales and leads a team of sales people spread across the US. With more than 15 years in sales experience in leading sales teams at web-based companies, his expertise lies in managing corporate customer relations.

Donna Palmer, PhD is Chief Scientific Officer, overseeing all aspects of the Brain Resource International Database and the scientific underpinnings of MyBrainSolutions products.

David Bogdonoff is VP of Technology and is responsible for development and operations of the MyBrainSolutions platform. He was previously VP of Product Services at Tickets.com, and Project Technology Director at WestEd.

Michael Kemper is Principal at Avant Experience. For almost 20 years, he has been producing award-winning design and software solutions for companies ranging from Fortune 100 companies to startups. Kemper’s team helps develop, maintain and support the MyBrainSolutions platform.

14

For

per

sona

l use

onl

y

Brain Resource Limited Cap Table & Financials

ASX: BRC, OTC: BRRZY - ADR 5:1

Ordinary shares $

IPO August 2001 (at 25.0 cents per share) 5,003,006

Total raised from 7 placements since IPO 13,518,472

Aug 14 Placement (25 cents per share) 7,027,500

Sep14 SPP (25 cents per share) 1,031,000

Total Equity Funds Raised to date ($) 26,579,978

Add: Och-Ziff Convertible equity (25cps)

Jun 11 Zero coupon Conv Bonds (exp Jun 16) 10,000,000

Dec 11 Exchangeable Convertible Pref Shares 4,000,000

Total Funds raised 40,579,978$

Summary of Share Register # Ord Shares Undiluted Diluted

Och Ziff Managed Funds 25,072,526 18.7% 42.7%

Spinite (High Net worth private) 16,711,311 12.5% 8.8%

Evian Gordon (Founder, Chairman & CEO) 11,456,249 8.6% 6.0%

Stuttgart (High Net worth private) 9,339,735 7.0% 4.9%

Dan Segal (Founder, Director & COO) 6,359,264 4.7% 3.3%

BRC Board members 2,002,239 1.5% 1.1%

70,941,324 53.0% 66.8%

Top 40 excluding the above 37,995,753 28.4% 20.0%

Other (around 440 small shareholders) 25,011,377 18.7% 13.2%

Total shares on issue (#) 133,948,454 100.0% 100.0%

Potential shares CB, ECPS 56,000,000

Total potential shares on issue (#) 189,948,454

• Financials include legacy revenues with transition underway to annuity product revenues. • Importantly, major expenditures on study recruitment and platforms are now complete, with

spend now primarily on marketing and revenue generation.

15

2015 2014

Revenues:

MyBrainSolutions - Employer 692,499 498,552 39%

MyBrainSolutions - Addiction 309,270 113,392 173%

MyBrainSolutions - Assessments 173,693 125,955 38%

MyBrainSolutions Total 1,175,462 737,899 59%

Other clinical reports 237,238 286,926

Treatment Prediction Research (iSPOT) 1,153,859 1,404,779

Other revenues 147,420 124,861

Total 2,713,978 2,554,465

Expenses:

Salaries and consultancy fees 2,535,198 2,161,260

Other 2,822,186 2,453,199

Total Expenses 5,357,384 4,614,459 16%

Loss before tax 2,643,406 2,059,994

Cash used in operations 3,131,834 1,428,954

Cash used in investing 2,765,494 2,314,163

Cash balance 4,335,282 1,992,611

Balance Sheet

Current Assets 5,491,425 2,408,272

Intangibles 28,483,939 26,693,111

Total Assets 38,051,296 32,666,458

Total Liabilities 15,630,090 15,438,614

Total Equity 22,421,206 17,227,845

For

per

sona

l use

onl

y

Follow up

Contact information

Evian Gordon CEO - Evian.Gordon@MyBrainSolutions.comDan Segal COO - Dan.Segal@MyBrainSolutions.com

Try MyBrainSolutions for yourself at www.mybrainsolutions.com/tryto assess your strengths and limitations in 30 mins and select a new habit to train for 30 days

(10 minutes, three times a week, for 4 weeks): for example reduce stress or improve self regulation.

16

For

per

sona

l use

onl

y

Disclaimer

This Presentation is being furnished solely for the purpose of enabling prospective investors to determine whether they wish toproceed with further investigation of the Company. This Presentation is not intended to form the basis of any investment decisionand does not attempt to present all the information that prospective investors may require for purposes of making an investmentdecision. The Company anticipates providing prospective investors with the opportunity to ask questions, receive answers, obtainadditional information and complete their own due diligence review concerning the Company prior to entering into any agreementrelating to the purchase of securities from the Company.

All information included in this Presentation is submitted to you on a strictly and permanently confidential basis. Any reproductionor further distribution of this Presentation or any such information is prohibited. By accepting delivery of this Presentation, youagree that neither you nor any of your employees, agents or advisors will use this Presentation or any such information for anypurpose other than evaluating the Company.

The Company shall not have any liability for any information included in this Presentation.

This Presentation speaks as of the date hereof. Nothing contained herein is, or should be relied upon as, a promise orrepresentation as to future performance. The Company does not undertake any obligation to update or revise the Presentation.

This Presentation is intended solely for the use of the prospective investor to whom this Presentation is initially provided. ThisPresentation does not constitute an offer to sell to or solicitation of an offer to purchase from any investor or in any jurisdiction inwhich such an offer or solicitation is not authorized, would be unlawful or would constitute an offer to the public pursuant to thelaws of such jurisdiction.

Any financial projections and other statements of anticipated future performance that are included in this Presentation are forillustrative purposes only and are based on assumptions by the Company’s management that are subject to significant risks anduncertainties and may prove to be incomplete or inaccurate. Actual results achieved may vary from our projections and thevariations may be material. Variations in the assumptions underlying our projections may also significantly affect projected results.

For

per

sona

l use

onl

y

Appendix slides

For

per

sona

l use

onl

y

Summary proof point examples

Addiction:• Playing MyBrainSolutions Games for around

3.5 hours has a statistically significant impact on Self Regulation Assessment scores and reduces clinical symptoms.

Employer:• Improvements based on employee surveys

and published data on improved scores from game play

i

For

per

sona

l use

onl

y

Macro US drivers

Major new legislation impacting demand:• Mandatory for health plans to cover mental health• Obamacare adds 30M+ added to the US health care system• Healthplans must cover selected preventive services at no charge (Depression

screening and Alcohol misuse)• Incentives (and penalties) for adopting electronic health records that have

‘meaningful use’ (ie decision support functionality)

# Respectively:Mental Health Parity and Addiction Equity Act, Patient Protection and Affordable Care Act and Hitech Act

ii

For

per

sona

l use

onl

y

Clinical Dashboard: Growth, scalability in Addiction

Tight integration with MyBrainSolutions• Seamless experience for Clinicians and Clients.

Low-touch, high-volume solution• Clinicians instantly create a MyBrainSolutions account. • MBS services available directly via the Dashboard. • Direct online payment

iii

For

per

sona

l use

onl

y

Unprecedented Asset Platform and Sales Growth Potential

Brain Resource Assets Development Total usage to date Users

Brain data acquisition and analysis software (EEG, MRI, Cognition)

30 years n/a 400 academic groups, 30 Pharma

Brain Resource International Database, standardized platform

15 years 225,000 datasets As above

iSPOT $18m study 9 years 5,200 acquisitions

Assessment 8 years 200,000 assessments

Training 5 years 9,500,000 game plays 140,000 users

10 Apps & Facebook games (iPad,Android, Facebook)

4 years 420,000 downloads

ADHD portal 3 years Pilot pilot

Clinical portal 3 years Version 3 recentlylaunched

Augmented therapy / User journeys 2 year In development

iv

For

per

sona

l use

onl

y